BCBSM/BCN Dual Header The Record Header Logo

The Record - Insurance Card with the BCBSM/BCN Cross and Shield logo that reads, Blue Cross Blue Shield, Blue Care Network of Michigan. Tagline: Confidence comes with every card. Image of Note boards with paper that has the letters RX on it accompanied by a stethoscope

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

May 2018

All Providers

May is Mental Health Month

May is Mental Health Month, a time to bring awareness to the importance of good mental health and to fight the stigma associated with mental health treatment.

At Blue Cross Blue Shield of Michigan, we understand the role that mental health plays in overall health and wellness. That’s why we launched our Integrating Behavioral Health into General Medical Care initiative three years ago, as part of our Physician Group Incentive Program.

New Directions Behavioral Health, a Blue Cross vendor that administers behavioral health services, has provided a toolkit of resources to help promote Mental Health Month. The resources include posters, infographics and articles on subjects such as “Four ways to enjoy life more” and “Addressing substance abuse in the workplace.”

We encourage you to check out the “Mind” section of A Healthier Michigan at ahealthiermichigan.org/mind for blogs highlighting mental health issues and the mind-body connection. Also, you can follow Blue Cross on Facebook and Twitter for Mental Health Month information.


Educate patients about how to safely dispose of unused drugs year-round

image 1 Prescription drug takeback days are often widely publicized, but many patients are unsure of how to dispose of unused pills at other times of the year. Unused pills in the home, especially opioids, can be dangerous or even deadly.

Your patients can find a disposal site in their local community through the Drug Enforcement Agency or Michigan Opioid Prescribing Engagement Network, called Michigan-OPEN. Both websites include a ZIP code locator to find a location nearby that provides a safe, convenient and anonymous way to dispose of medications year-round.

Find a local opioid drop-off location near you:

If no medication takeback program or facility is available for your patients, they can follow some simple steps from the Food and Drug Administration to dispose of most medications in their home as a last resort. However, the ideal way to dispose of unused drugs is to participate in a takeback event, such as National Prescription Drug Take Back Day, or take them to a drug disposal facility.

“It can be tempting for patients to keep unused pills on hand for future use, but they can easily get into the wrong hands of a curious teen or someone already addicted,” said Jody Gembarski. Pharm.D., a clinical pharmacy manager with Blue Cross Blue Shield of Michigan. “More than three out of four people who misuse prescriptions use drugs that are prescribed to friends and family.”

Remind your patients that while medications play an important role in treating many health conditions, it’s important to dispose of them properly to avoid harm to others when they’re no longer needed.


MAPS’ new technology may help providers identify substance abuse disorders

New state requirements
Licensed prescribers who prescribe or dispense a controlled substance to a patient will need to register with MAPS. And before prescribing or dispensing a controlled substance exceeding a three-day supply, the prescriber must obtain and review a report from MAPS.

This helps to ensure safe and appropriate prescribing based on other controlled substances the patient may be receiving with or without your knowledge. Some exceptions do apply, such as controlled substances dispensed in a hospital or outpatient facility and administered directly to the patient.

For more details, see Public Acts 248 and 252 of 2017.

The Michigan Automated Prescription System, or MAPS, began using a new technology platform late last year. This resulted in changes in the type of information provided and how it’s displayed.

MAPS is a tool used by prescribers and dispensers to assess patient risk. It also helps to prevent drug abuse and diversion at the prescriber, pharmacy and patient levels.

The new technology will help providers make better informed decisions when it comes to identifying, preventing and managing substance use disorders.

Here’s an overview of what you’ll currently find on MAPS:

Related image

Risk scores, based on the number of providers and pharmacies, morphine milligram equivalents and overlapping prescriptions, are intended to help aid in decision-making. Scores are available for narcotics, sedatives and stimulants, including risk of unintentional overdose death.

1

Interactive, color-coded prescription graphs provide the patient’s prescription history and incorporates morphine milligram equivalents.

2

A ZIP code locator is available to find Substance Abuse and Mental Health Services Administration-supported medication-assisted treatment providers. The report generates a list of 30 SAMHSA-supported providers closest to the patient.

3

Printable pamphlets to give to patients are available on topics such as safe pain management, what to know about opioids and an overdose tip card. Prescribing checklists and other resources are available for providers.

4

Prescribers can view a personalized report of their controlled substance prescriptions for the last four quarters.


Battling the opioid epidemic: A roundup of news and information

We hope this information is useful as you continue your efforts to combat the opioid epidemic.

Resources help providers communicate about risks, benefits of opioid therapy

image2The Centers for Disease Control and Prevention offers resources to support its CDC Guideline for Prescribing Opioids for Chronic Pain. The resources were designed to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment and reduce the risks associated with long-term opioid therapy, including opioid use disorder, overdose and death. You can access them by clicking here.

Reminder: MQIC guideline for opioid use in adults

Here’s a recap of key recommendations from the Michigan Quality Improvement Consortium’s guideline called Opioid Use in Adults Excluding Palliative and End-of-Life Care:

  • Treat pain with non-drug therapy and non-opioid medications when possible.
  • Screen for risk of dependence.
  • Obtain a Prescription Drug Monitoring Program report.
  • Perform urine drug testing when warranted.
  • Discuss risks of dependency, overdose and death.
  • Prescribe the lowest effective dose — three days or fewer for acute pain.
  • Discuss realistic goals for pain and function, including discontinuing therapy if benefits don’t outweigh the risks; re-evaluate pain and function throughout the treatment period.
  • Avoid prescribing opioids with benzodiazepines, muscle relaxants or hypnotics.
  • Consider offering the patient or family member naloxone when there are risk factors for overdose. (Following naloxone use, the patient should be seen immediately in a hospital emergency department.)
  • When considering increasing dosage to > 90 MME/day, reassess evidence of individual benefits and risks.
  • Avoid renewal without clinical reassessment.

The MQIC guideline was based on the CDC Guideline for Prescribing Opioids for Chronic Pain. To read the MQIC guideline, click here

Mi-CCSI to offer basic and advanced pain management training

The Michigan Center for Clinical Systems Improvement, or Mi-CCSI, in collaboration with its members and community organizations, has developed a comprehensive training program to address patients with acute and chronic pain. The curriculum includes the foundations of pain management, which addresses:

  • Basics of pain management mechanisms
  • Pathophysiology
  • Biopsychosocial aspects of pain
  • Pharmacotherapy
  • Non-pharmacy treatment approaches

The advanced practical workshops include:

  • Approaches for medication tapering
  • Conducting difficult conversations with patients
  • Comprehensive assessment of biopsychosocial aspects of pain
  • Basics of addiction
  • Referral and communications strategies with specialty providers
  • Using the new automated prescription system

The intended audience includes primary care practice teams or individual providers and clinical and nonclinical staff, including care managers, social workers, medical assistants, office managers and staff, pharmacists and behavioral health specialists.

The dates, locations and registration link are in the table below.

Date

Location

Registration website

June 21

Traverse City
Park Place Hotel

miccsi.org/training/pain-management-training

Oct. 12

Grand Rapids
Masonic Center

Oct. 13

Muskegon
Holiday Inn-Harbor

Oct. 30

Wixom/New Hudson
Blue Cross Lyon Meadows Conference Center

Nov. 20

Wixom/New Hudson
Blue Cross Lyon Meadows Conference Center

For more information about efforts to address the opioid epidemic, see the articles on appropriate drug disposal and the Michigan Automated Prescription System, also in this issue.

None of the information included in this article is intended to be legal advice.


HCPCS update: New codes added

The Centers for Medicare & Medicaid Services has added several new codes as part of its quarterly Health Care Procedure Coding System updates. The codes, effective dates and Blue Cross Blue Shield of Michigan’s coverage decisions are below.

Medicine/professional — Miscellaneous/data gathering

Code

Change

Coverage comments

Effective date

G9873

Added

Not covered

April 1, 2018

G9874

Added

Not covered

April 1, 2018

G9875

Added

Not covered

April 1, 2018

G9876

Added

Not covered

April 1, 2018

G9877

Added

Not covered

April 1, 2018

G9878

Added

Not covered

April 1, 2018

G9879

Added

Not covered

April 1, 2018

G9880

Added

Not covered

April 1, 2018

G9881

Added

Not covered

April 1, 2018

G9882

Added

Not covered

April 1, 2018

G9883

Added

Not covered

April 1, 2018

G9884

Added

Not covered

April 1, 2018

G9885

Added

Not covered

April 1, 2018

G9890

Added

Not covered

April 1, 2018

G9891

Added

Not covered

April 1, 2018

Temporary codes — Durable medical equipment

Code

Change

Coverage comments

Effective date

K0903

Added

Covered

April 1, 2018

Medicine supplementary — Injections

Code

Change

Coverage comments

Effective date

Q2041

Added

Requires manual review

April 1, 2018

Q5102

Deleted

Deleted

March 31, 2018

Q5103

Added

Requires manual review

April 1, 2018

Q5104

Added

Requires manual review

April 1, 2018

Modifiers

Modifier

Change

Coverage comments

Effective date

QA

Added

Informational only

April 1, 2018

QB

Added

Informational only

Jan. 1, 2018

QR

Added

Informational only

April 1, 2018

ZA

Deleted

Deleted

March 31, 2018

ZB

Deleted

Deleted

March 31, 2018

ZC

Deleted

Deleted

March 31, 2018

Outpatient Prospective Payment System — Injection

Code

Change

Coverage comments

Effective date

C9462

Added

Covered for facility only

April 1, 2018

C9463

Added

Covered for facility only

April 1, 2018

C9464

Added

Covered for facility only

April 1, 2018

C9465

Added

Not covered

April 1, 2018

C9466

Added

Covered for facility only

April 1, 2018

C9467

Added

Covered for facility only

April 1, 2018

C9468

Added

Covered for facility only

April 1, 2018

C9469

Added

Covered for facility only

April 1, 2018

Outpatient Prospective Payment System — Surgery

Code

Change

Coverage comments

Effective date

C9749

Added

Covered for facility only

April 1, 2018

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Billing chart: Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

J3490, J3590

Basic benefit and medical policy

Luxturna will require prior authorization.

Luxturna™ (voretigene neparvovec-rzyl) is approved and will require prior authorization.

Luxturna (voretigene neparvovec-rzyl) is considered established when criteria are met, effective Feb. 1, 2018.

  1. Coverage of the requested drug is provided when all the below criteria are met:
    1. Prescribed for an FDA-approved indication
    2. Prescribed and administered by an ophthalmologist
    3. Documentation of biallelic RPE65 gene mutation
    4. Visual acuity of 20/60 or worse in both eyes or a binocular visual field less than 20 degrees in any meridian
    5. Retinal thickness of >100 microns within the posterior pole

  2. Quantity limitations, authorization period and renewal criteria
    1. Quantity limit: Maximum one injection per eye, lifetime
    2. Initial authorization period: One month
    3. Renewal criteria: None. One lifetime injection per eye

  3. Voretigene neparvovec-rzyl is considered investigational when used for all other conditions including, but not limited to:
    1. Other types of Leber congenital amaurosis (e.g., Type 3, Type 15)
    2. Other inherited retinal disorders

  4. FDA-approved indication and diagnosis for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. 

Patient must have viable retinal cells as determined by the treating physician.

Note: Requests must be supported by submission of chart notes and patient specific documentation.

Verify group coverage for Luxturna.

UPDATES TO PAYABLE PROCEDURES

81401, 81405, 81408, 81410, 81411, 81479**

**Unlisted procedure used for individual mutation testing of genes not coded by CPT*

Basic benefit and medical policy

Genetic testing for Marfan and other syndromes associated with thoracic aortic aneurysms

The safety and effectiveness of genetic testing for Marfan syndrome and other syndromes associated with thoracic aortic aneurysms and dissections, and related disorders have been established. It may be considered a useful diagnostic option when indicated. Inclusionary and exclusionary criteria have been updated, effective May 1, 2018.

Inclusions:

Individual genetic testing for the diagnosis of Marfan syndrome and other syndromes associated with thoracic aortic aneurysms and dissections, and related disorders when one of the following occurs:

  • Focused genetic testing of the following genes: FBN1, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, MYLK, TGFBR1 and TGFBR2
  • A panel of at least nine genes that must include FBN1, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, MYLK, TGFBR1 and TGFBR2 when one of the following occurs:
    • Signs and symptoms of a connective tissue disorder are present, but a definitive diagnosis can’t be made using established clinical diagnostic criteria (e.g., Ghent criteria).
    • Assessing future risk of disease in an asymptomatic individual when there is a known pathogenic variant in the family.

Exclusions:

  • Genetic testing panels for Marfan syndrome and other syndromes associated with thoracic aortic aneurysms and dissections, and related disorders that don’t include genes listed under inclusions
  • For the prenatal or pre-implantation genetic diagnosis of Marfan syndrome in the offspring of patients with known disease-causing variants
GROUP BENEFIT CHANGES

19303, 19304, 19318, 19350, 54520, 55970, 55980, 56805, 57291, 57292, 57335, 58150, 58152, 58180, 58260, 58262, 58275, 58291, 58541, 58542, 58543, 58544, 58550, 58552, 58553, 58554

Not covered:

11950, 11951, 11952, 11954, 15820, 15821, 15822, 15823, 15824, 15825, 15826, 15828, 15830, 15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839, 15876, 15877, 15878, 15879, 17380*, 21120, 21121, 21122, 21123, 21125, 21127, 30400, 30410, 30420, 30430, 30435, 30450

Basic benefit and medical policy

Transgender services

The safety and effectiveness of select medical and surgical treatments of gender dysphoria have been established. The established treatments of gender dysphoria include:

  • Puberty suppression in adolescents
  • Cross-sexual hormone therapy (for masculinization or feminization)
  • Medically necessary gender reassignment surgery:**
    • Genitalia reconstruction
    • Mastectomy in female-to-male transitions

**Gender reassignment surgery may require prior authorization.

Gender-specific services may be medically necessary for transgender people appropriate to their anatomy. Examples include:

  • Breast cancer screening may be medically necessary for female-to-male transitioned people who haven’t undergone a mastectomy.
  • Prostate cancer screening may be medically necessary for male-to-female transitioned people who have retained their prostate.
  • Cervical screening may be medically necessary for female-to-male transitioned people, as needed.

The policy has been reviewed and updated, effective May 1, 2018.

Group variations:

Verify member benefits to determine eligibility.

Inclusions:

Assessment, diagnosis and treatment should be provided through a multidisciplinary gender services clinic or program affiliated with a major medical center. If this level of service is unavailable, there should be documentation that reflects a coordinated approach to care by specialists involved (mental health specialists, physicians, surgeons, etc.).

Puberty suppression**

Puberty suppression hormones for adolescents may be indicated for members who meet all the following inclusionary criteria:

  • Onset of puberty to at least Tanner stage 2.
  • The adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed).
  • Gender dysphoria emerged or worsened with the onset of puberty.
  • Any coexisting psychological, medical or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent’s situation and functioning are stable enough to start treatment.
  • The adolescent has given informed consent and, particularly when the adolescent hasn’t reached the age of medical consent, the parents or other caretakers or guardians (must have legal authority to consent on behalf of a non-emancipated minor) have consented to the treatment and are involved in supporting the adolescent throughout the treatment process.
  • The absence of contraindications to therapy in the judgment of the managing physician.

**Medications for puberty suppression may be managed under the member’s pharmacy benefit.

Hormone therapy**

Hormone therapy may be indicated for members who meet all the following inclusionary criteria:

  • Persistent, well-documented gender dysphoria.
  • Capacity to make a fully informed decision and to consent for treatments.
  • Eighteen years of age or older (age of majority).
  • If significant medical or mental health concerns are present, they must be reasonably well-controlled.
  • The absence of contraindications to therapy in the judgment of the managing physician.

**Medications for hormone therapy may be managed under the member’s pharmacy benefit.

Gender reassignment surgery

Gender reassignment surgery may be indicated for members who meet all the following inclusionary criteria:

  • Persistent, well-documented gender dysphoria.
  • The provider must supply documentation that supports the member meets criteria for gender reassignment surgery.
    • This includes detailed psychological assessments by two mental health providers: either psychiatrist, PhD prepared clinical psychologist or master’s prepared clinicians who are licensed to practice independently in their state.
  • Eighteen years of age or older.
  • Capacity to make a fully informed decision and to consent for treatment.
  • If significant medical or mental health concerns are present, they must be controlled.
  • Twelve continuous months of hormone therapy** as appropriate to the patient’s gender role (unless there is a contraindication to hormonal therapy).
    • **Hormonal therapy is not required prior to mastectomy in biological female-to-male patients.
    • The aim of hormone therapy prior to gonadectomy is primarily to introduce a period of reversible estrogen or testosterone suppression, before the patient undergoes irreversible surgical intervention.
  • Twelve continuous months of living in a gender role that is congruent with their gender identity.
    • **Living in a gender role congruent with gender identity for 12 continuous months is not required prior to mastectomy in biological female-to-male patients.
  • If gender reassignment surgery is approved for a biological male transitioning to female, permanent hair removal (by electrolysis) may be considered established following medical review. Permanent hair removal is considered established only when the scrotal and surrounding tissues are used in the surgical construction of the vagina.

Some patients receiving transgender services may require and benefit from ongoing behavioral health services, including psychotherapy.

Exclusions:

  • Transgender services aren’t covered if contract or certificate language contains specific exclusion of these services.
  • Reversal of transgender surgical procedures.
  • All surgical procedures that are primarily cosmetic and not medically necessary including, but not limited to:
    • Abdominoplasty
    • Blepharoplasty
    • Breast enhancements
    • Brow lift
    • Calf implants
    • Cheek/malar implants
    • Chin/nose implants
    • Chondrolaryngoplasty (Adam’s apple reduction)
    • Collagen injections
    • Construction of a clitoral hood
    • Drugs for hair loss or growth
    • Forehead lift
    • Hair removal
    • Hair transplantation
    • Lip reduction
    • Liposuction
    • Mastopexy
    • Neck tightening
    • Pectoral implants
    • Removal of redundant skin
    • Rhinoplasty
    • Speech-language therapy
    • Non-covered services

36473, 36474, 36482, 36483

Basic benefit and medical policy

Endovenous ablation for the treatment of varicose veins

Endovenous ablation of varicose veins by mechanochemical (ClariVein®) or cyanoacrylate embolization (VenaSeal™) is experimental. These procedures haven’t been scientifically demonstrated to be as safe and effective as conventional treatment, effective May 1, 2018.

81210, 81275, 81276, 81311, 81403, 81404, 88363

Basic benefit and medical policy

Genetic testing for KRAS, NRAS and BRAF mutation analysis in metastatic colorectal cancer

The safety and effectiveness of KRAS, NRAS and BRAF mutation analyses have been established and may be considered a useful diagnostic option to predict nonresponse to anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of all patients with metastatic colorectal cancer. It’s a useful therapeutic option when indicated.

Inclusions:

KRAS, NRAS and BRAF mutation analysis in patients with metastatic colorectal cancer in order to determine their nonresponse to EGFR inhibitor drugs such as Vectibix® (panitumumab) and Erbitux® (cetuximab).

The effective date is May 21, 2018.

81406

Basic benefit and medical policy

Genetic testing of CADASIL syndrome

The criteria have been updated for the Genetic Testing of CADASIL Syndrome policy. The effective date is May 21, 2018.

Inclusions:

  • Genetic testing of NOTCH3 to confirm the diagnosis of CADASIL syndrome in an individual is considered established under all the following conditions:
    • Clinical signs, symptoms and imaging results are suggestive of CADASIL
    • A score of 15 or more on the following CADASIL Scale
    • Either a. or b. below

CADASIL Scale (Pescini et al., 2012)

Migraine

1

Migraine with aura

3

TIA or stroke

1

TIA/stoke onset ≤50 y

2

Psychiatric disturbances

1

Cognitive decline/dementia

3

Leukoencephalopathy

3

Leukoencephalopathy extended to temporal pole

1

Leukoencephalopathy extended to external capsule

5

Subcortical infarcts

2

Family history** in at least 1 generation

1

Family history** in at least 2 generations

2

The total score (ranging from 0 to 25) is obtained by the sum of the score attributed to each variable. A total score of ≥15 is predictive of CADASIL diagnosis.

**For at least one of the typical disturbances (headache, transient ischemic attack/stroke, cognitive decline, psychiatric disturbances).

    1. Testing for the NOTCH3 variant is being performed to avoid an invasive procedure (skin biopsy).
    2. The diagnosis of CADASIL is inconclusive following alternate methods of testing, including skin biopsy and magnetic resonance imaging.
  • Genetic testing for CADASIL syndrome of an asymptomatic individual who has a first- or second-degree relative with CADASIL is established under the following conditions:
    • If there is a family member (first- or second-degree) with a known variant, targeted genetic testing of the known NOTCH3 familial variant is considered established.
    • If the family member’s genetic status is unknown, genetic testing of NOTCH3 is considered established.

Note: A first-degree relative is a parent, full-sibling or child. A second-degree relative is a grandparent, grandchild, aunt, uncle, nephew, niece or half-sibling.

Exclusions:

  • If skin biopsy results in a diagnosis of CADASIL syndrome, genetic testing for the NOTCH3 variant isn’t medically necessary.
  • All other situations not addressed in the inclusions above are excluded.

84999**

**Not otherwise classified procedure

Basic benefit and medical policy

Measurement of antibodies to infliximab, adalimumab or vedolizumab

Measurement of antibodies to infliximab, adalimumab, or vedolizumab in a patients receiving treatment with infliximab, adalimumab or vedolizumab, whether alone or as a combination test that includes the measurement of serum infliximab, adalimumab or vedolizumab levels, is considered experimental. The use of these tests hasn’t been clinically proven to improve patient clinical outcomes or alter patient management. The updated policy is effective May 1, 2018.

G0463

Basic benefit and medical policy

Procedure code G0463

HCPCS procedure code G0463 has been updated to allow reimbursement when reported in a hospital outpatient setting with an appropriate revenue code for supplemental and exact fill contracts.

J7178

Basic benefit and medical policy

Congenital fibrinogen deficiency

Payable for FDA-approved indication of congenital fibrinogen deficiency, effective June 7, 2017.

S1034, S1035, S1036, S1037

Basic benefit and medical policy

Artificial pancreas device systems

The criteria have been updated for the Artificial Pancreas Device Systems policy. The effective date is May 1, 2018.

Inclusions:

Use of a FDA-approved artificial pancreas device system with a low-glucose suspend feature may be considered established in patients with insulin-requiring diabetes who meet all the following criteria:

  • Age 16 or older.
  • Insulin requiring diabetes.
  • Used CGMS pump for more than six months.
  • Have at least two documented nocturnal hypoglycemic events to which member has not responded.
EXPERIMENTAL PROCEDURES

0485T, 0486T

Basic benefit and medical policy

Optical coherence tomography of the middle ear (e.g., Photonicare Clearview® System)

Optical Coherence Tomography, or OCT, of the middle ear isn’t an established procedure. While this service may be safe, its effectiveness in this clinical indication hasn’t been scientifically determined. Therefore, this service is experimental. This policy is effective May 1, 2018.

21499, 26989, 22999, 30999, 31599, 31899, 42999, 55899, 67599, 69399

Basic benefit and medical policy

Composite tissue allotransplantation of the hand or face

Composite tissue allotransplantation of the hand or face is experimental. There is insufficient evidence in the published peer-reviewed medical literature to demonstrate the safety and effectiveness of these procedures.

Other composite tissue allotransplantation that is experimental includes, but is not limited to:

  • Auricular
  • Nasal
  • Human eye
  • Larynx/Pharynx
  • Trachea
  • Penile
  • Uterus
  • Abdominal wall
  • Lower limb

This policy is effective May 1, 2018.

81328

Basic benefit and medical policy

Genetic testing for statin-induced myopathy

The peer-reviewed medical literature hasn’t demonstrated the clinical utility of genetic testing for the presence of variants in the SLCO1B1 gene to identify patients at risk of statin-induced myopathy. Therefore, this service is considered experimental. This policy is effective May 1, 2018

G0475, 87633, 87801

Basic benefit and medical policy

Codes added to Physician Office Laboratory List

These codes have been added to the Physician Office Laboratory List. They can be performed in a physician’s office.


Professional

Here are more details about changes to our professional provider consultant model

In the March Record, we told you we’d give you more details about upcoming changes to the Blue Cross Blue Shield of Michigan and Blue Care Network professional provider consultant servicing model in future issues. Here’s an overview of what’s changing and how we believe these changes will benefit health care providers going forward.

What’s changing

  • We’re encouraging professional providers to always use the standard methods of communicating with us when first contacting us for information or assistance. These are outlined in our resource guides for Blue Cross and BCN.
  • We’re improving our processes to better answer your questions and direct you to helpful tips and online information when you contact us the first time.
  • We’ll soon be assigning our professional consultants to serve specific Blue Cross Physician Group Incentive Program physician organizations, known as POs, and Blue Care Network medical care groups, or MCGs, to provide education and training on our policies and programs.

How this will help you

  • By directing health care providers to standard sources of information, such as Provider Inquiry, we can better identify problems, prioritize efforts and fix problems affecting multiple providers versus addressing issues one practice at a time.
  • By improving our processes, we expect you’ll see incremental improvements, resulting in higher levels of satisfaction over time.
  • By partnering more closely with POs and MCGs, group administrators can help us focus our educational efforts where they’re needed most.

What you need to know

Here are some important points to keep in mind.

  • Contact Provider Inquiry for all claims issues. All professional claims inquiries must be directed to Provider Inquiry (1-800-344-8525 for medical providers; 1-800-482-4047 for vision and hearing providers), even complex claims issues. If your issue isn’t satisfactorily resolved, ask the representative to escalate your inquiry to their leadership.
  • Consider joining a physician organization or a medical care group if you’re not already part of one. With the evolution of value-based reimbursement programs, you’ll receive the support you need to transition to a population management-based health care delivery system. Take a look at the groups that are available and see which one is a good fit for your practice.
  • Our hospital and facility consultants haven’t changed. Most provider consultant assignments for hospitals and facilities haven’t changed, and the assistance they provide remains the same. If you’re with a hospital or facility, here’s how you can check your assigned provider consultant:
    • Go to bcbsm.com/providers.
    • Click on Contact Us in the right-hand corner of the page.
    • Under Hospitals and facilities, click on either Blue Cross Blue Shield of Michigan provider contacts or Blue Care Network provider contacts.
    • Click on Provider consultants.

We value your input about these changes. If you have specific comments or suggestions, contact provideroutreach@bcbsm.com.

We know it will take some time to transition to this new service model and perfect it, and ask for your patience over the next few months as we implement these changes.


We’ve modified provider appeal time frames, effective June 1

In a March Record article, we let you know that changes were coming to how we’re handling provider audits and appeals. Here are the time frames associated with the provider audit appeals process for professional and non-hospital facility providers, beginning June 1, 2018.

For reconsideration appeal:

  • The health care provider must request an appeal within 30 calendar days of the date on the reporting letter.
  • The provider will receive a response to his or her appeal within 30 calendar days of the date the appeal is received.
  • We’ll adjust claims as needed if we don’t receive a reconsideration appeal within 30 calendar days of the date of the audit finding.

For independent external review:

  • We must receive the request for a review within 30 calendar days of the date of the reconsideration appeal letter.
  • An external peer review of records will take place within 45 calendar days.
  • The provider will be notified of the peer review decision within 30 calendar days of the date that the peer review decision is received.
  • The provider will pay the cost of the peer review if our audit decision is upheld. If our audit decision is reversed, then we’ll absorb the cost. If our findings are partially reversed and partially upheld, we will share the peer review cost proportionate to the results.
  • We’ll adjust claims as needed if we don’t receive a request for an independent external review within 30 calendar days of the date of the appeal uphold letter.

Note: Providers may incur attorney fees and other expenses in preparation for the external peer review; these costs are the providers’ responsibility. The external review ends the appeal process for both Blue Cross Blue Shield of Michigan and the provider.


Benefit Explainer e-learning available

We’ve created a 25-minute, online training presentation for Benefit Explainer. It includes a general overview of the application and how to:

  • Perform a Benefit Package Report search.
  • Read and interpret BPR search screens.
  • Search for general medical and payment policy rules and provider manuals.

The presentation also highlights the new Online Benefits Information tab and other recent upgrades announced in the August 2017 Record article titled “We’re making changes to Benefit Explainer.”

To access the presentation, go to brainshark.com/bcbsm.com/bcbsm/benefit-explainer or visit the Provider Training section of web-DENIS.

  • From the home page of web-DENIS, click on BCBSM Newsletters and Resources.
  • Click on Newsletters and Resources.
  • Click on Provider Training. (The presentation is in the Featured Links section.)

When you access the presentation for the first time, you’ll be asked to sign a guestbook. Check the “Remember Me” box so you can pick up where you left off if you need to stop watching at any point.

Note: Blue Cross Blue Shield of Michigan won’t send solicitation emails or provide your information to anyone for other purposes.


Providers to have one contact for post-acute care authorizations

As Blue Cross Blue Shield of Michigan continues to align functions across our organization, we’ve created a single point of contact for providers to request an authorization for post-acute care admissions, including skilled nursing facilities and long-term acute care hospitals.

As of April 30, 2018, all these requests should be routed to the Precertification Utilization Management team by faxing them to 1-866-411-2573. The process for requesting authorizations can be found here and the forms for faxing can be found on this page, under Forms. As part of the process, all benefits must be verified before you request services.

The Precertification Utilization Management team provides authorizations for acute inpatient hospital settings, inpatient rehabilitation, SNF and Medicare Advantage PPO LTACH cases.

Case Management won’t process requests for enhanced benefits for SNF, LTACH or other extra-contractual benefits as of April 30. These requests will be processed by Precertification Utilization Management. Case Management will continue to process cases for care coordination only. The number for the Blue Cross Engagement Center is 1-800-775 2583.

MESSA is excluded from the precertification and case management programs outlined in this article. All other commercial employer groups, including the auto groups and the URMBT, are included, as well as individual members and Federal Employee Program® members.

If you have any questions, check out the links above.


Take this advice to help ensure your Medicare patients take their medications

Medication adherence is critical to Medicare patient quality outcomes. The Centers for Medicare & Medicaid Services has stressed the importance of medication adherence by including three triple-weighted clinical pharmacy measures in the star ratings program for Medicare Advantage health care plans.

The three medication adherence measures cover medications for diabetes, hypertension and cholesterol. Member compliance for these three measures is based on the percentage of plan members who fill their diabetes, hypertension or cholesterol prescriptions often enough to cover 80 percent or more of the time they’re supposed to be taking the medication.

Why are patients non-adherent and what can you do to help them?
Here are common reasons why patients don’t take their medication as prescribed and ways you can encourage their compliance.

The patient forgets to refill the prescription on time.

Consider writing 90-day supplies of any maintenance medications. A study published in The American Journal of Managed Care showed that patients on 90-day supplies were more adherent than patients on 30-day supplies.

A patient thinks the medication costs too much.

If cost is a concern, especially with a brand-name medication, consider switching the patient to a lower-cost generic medication if possible.

If there is another brand-name medication in the same class, one brand may be preferred over the other by the patient’s health care plan and have a lower co-pay.

It’s not recommended for physicians to prescribe a double dose to financially disadvantaged patients and tell them to cut the medication in half. This could result in mismatched printed and verbal directions, which could lead to patient or caregiver confusion.

A patient isn’t convinced that the medication is important, or the patient thinks taking the medication would be harmful.

While any drug carries possible risk, stress the potential adverse consequences for the patient if he or she doesn’t take the medication as prescribed. The benefits of the medication should outweigh the risk.

Tell the patient to let you know immediately if he or she experiences side effects. The patient shouldn’t stop or change the regimen on his or her own, because there are ways to manage side effects.

For example:

  • Lowering a dose
  • Taking medications with food or water
  • Taking medications at bedtime instead of during the day
  • Changing from an immediate-release to an extended-release formulation
  • Changing to a different medication within the same class

It’s difficult for a patient to remember taking the medication when he or she must.

Offer the following suggestions:

  • Using weekly or monthly pill boxes
  • Setting cellphone reminder alarms
  • Making use of medication adherence smartphone apps
  • Placing medications in a highly visible area (but in properly closed containers and safely out of reach of children or pets)

A patient is unable to get to the pharmacy because of unreliable transportation.

Inform the patient that many pharmacies offer delivery services, and mail-order pharmacy is an option as well.

As a physician, you can have a huge effect on medication adherence. Your insight can help identify reasons why patients struggle with medication adherence, and your expertise can help guide them to healthier outcomes.

Sources:

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all medical services are done in accordance with all applicable state and federal laws and regulations.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Here’s what you need to know about colorectal cancer screening

Colorectal cancer screening, a HEDIS® measure, examines the percentage of adults ages 50 to 75 who get the appropriate screening for colorectal cancer. It excludes patients with a history of colorectal cancer or a total colectomy as well as those in hospice.

Important reminders:

  • Begin colorectal screening at age 50 and monitor screening in accordance with screening guidelines. For high-risk patients, begin screenings sooner.
  • Perform patient outreach to ensure they complete testing.
  • Once the patient is screened for colorectal cancer, submit a claim and document the name of the test, date performed and results in the patient’s medical record.

How to ensure you’re meeting HEDIS specifications (closing the gap):
These preventive screenings meet HEDIS specifications for an appropriate screening for colorectal cancer:

Procedure

HEDIS specifications

Notes

Screening colonoscopy

Every 10 years

 

Screening flexible sigmoidoscopy

Every five years

 

Screening CT colonography

Every five years

While it meets HEDIS screening requirements, Medicare doesn’t reimburse for it as of April 1, 2017

FIT DNA (e.g., Cologuard®)

Every three years

Visit https://www.cologuardtest.com/hcp/ordering-cologuard/how-to-order-the-test to order the test by fax or online

Fecal occult blood test (e.g., FIT, iFIT, guaiac)

Every year

Performing fecal occult testing on a sample collected from a rectal exam doesn’t meet screening criteria by the American Cancer Society or HEDIS.

HEDIS®, which stands for Healthcare Effectiveness Data and Information Set, is a registered trademark of the National Committee for Quality Assurance.


Here’s how to accurately code for immunosuppression and immunodeficiency

Patients on immunosuppressant medications are commonly assigned a diagnosis code for immunodeficiency. However, in the American Hospital Association’s manual on ICD-10-CM codes, immunosuppression and immunodeficiency are not synonymous. They’re represented by distinctly different ICD-10-CM codes.

Immunodeficiency
Immunodeficiency is caused by a malfunction of the immune system. This malfunction can be either congenital (primary) or acquired.

Congenital immunodeficiency
There are more than 100 primary immunodeficiency disorders, classified by the specific part of the immune system they affect. Examples include:

  • Common variable immunodeficiency
  • Bruton’s disease
  • Severe mixed immunodeficiency syndrome
  • Deficiency of a specific antibody
  • Cyclic neutropenia

Acquired immunodeficiency
This can occur in one of two ways:

  1. As a side effect or adverse effect of a medication that’s correctly prescribed and properly administered. The medicine is used to treat an underlying disease without the intent to alter the immune state, such as antineoplastic chemotherapy drugs or radiation.**

    Example: The physician documents that the patient is immune deficient due to chemotherapy used for treating cancer. The correct code assignment would be T45.1X5-, adverse effect of antineoplastic and immunosuppressive drugs. The required 7th digit is dependent on if the patient is receiving active treatment (A), routine care during the healing or recovery phase (D) or treatment for complications or conditions that arise directly from the condition (S).

  2. As the result of a disease or disorder, such as:
    • Cancer
    • A human immunodeficiency virus infection leading to acquired immunodeficiency syndrome, or AIDS

Immunosuppression
Immunosuppression is caused by medications prescribed to intentionally suppress the immune system. These medications are used to treat various autoimmune diseases, including:

  • Rheumatoid arthritis
  • Sjogren’s syndrome
  • Psoriasis
  • Crohn’s disease

By suppressing the overreactive immune system in patients with these conditions, the immune response triggering the disease process is weakened. Weakening the immune response helps promote remission in afflicted patients.

Immunosuppressant medications are also required for patients who have had an organ transplant. Since the immune system is designed to attack anything foreign within our body, transplanted organs are no exception. By suppressing the immune system, the body is less likely to reject the transplanted organ.

Example: A physician documents that a patient has an immune deficiency and is taking immunosuppressants. The doctor should use code Z79.899 to represent the patient’s long-term immunosuppressant medication therapy. The ICD-10-CM code for immunodeficiency doesn’t provide a specific code to identify these drugs. Since this patient is taking the immunosuppressant medication, with the intent to suppress the immune system, codes for immunodeficiency that’s caused by an adverse effect of drug treatment or from an underlying disease should not be assigned.**

**AHA Coding Clinic for ICD; 2015; third quarter


Provider forums kick off in May

As you read in The Record last month, Blue Cross Blue Shield of Michigan and Blue Care Network’s 2018 provider forums will be held from May through June at various locations across the state.

The morning sessions will have content specifically geared to physician office staff who are responsible for closing gaps related to quality measures and coding. A special morning presentation on understanding the patient experience will be targeted to office managers and staff.

Topics for the morning sessions will include:

  • The patient experience — why it’s important to your practice and how you can improve it
  • HEDIS® measures
  • 2018 CPT updates and coding scenarios for primary care physicians and specialists

Afternoon sessions will be geared toward all office personnel and will cover topics such as:

  • New provider service model
  • Authorizations
  • e-referral
  • The opioid epidemic
  • Behavioral health
  • Updates for Provider Enrollment and Data Management and the Provider Automated Response System

Here’s the schedule of events:

  • Registration begins at 7:30 a.m.
  • The morning session starts at 8 a.m., includes a continental breakfast and ends at 11:30 a.m.
  • The afternoon session begins at noon, includes lunch and ends at 4 p.m.

You can register for the full day or choose to attend just the morning or afternoon session.

These forums provide valuable information to keep your staff up to date on the latest developments. We look forward to seeing you soon.

Novi
Four Points Sheraton
27000 S. Karevich Drive
Novi, MI 48377

Tuesday, May 8, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Pontiac/Auburn Hills
Crowne Plaza
1500 N. Opdyke Road
Auburn Hills, MI 48326

Thursday, May 10, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Grand Rapids
DoubleTree Grand Rapids Airport
4747 28th St. SE
Grand Rapids, MI 49512

Tuesday, May 15, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Kalamazoo
The Fetzer Center
Western Michigan University
2251 Business Court Kalamazoo, MI 49008

Wednesday, May 16, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Ann Arbor
Courtyard Ann Arbor
3205 Boardwalk
Ann Arbor, MI 48108

Tuesday, May 22, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Sterling Heights
Wyndham Garden
34911 Van Dyke
Sterling Heights, MI 48312

Thursday, May 24, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Port Huron
DoubleTree by Hilton
800 Harker St.
Port Huron, MI 48060

Tuesday, June 5, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Okemos/Lansing
Lansing Community College
5078 Cornerstone Drive
Lansing, MI 48917

Thursday, June 7, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Traverse City
West Bay Beach
615 E. Front St.
Traverse City, MI 49686

Tuesday, June 12, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Marquette
Holiday Inn Marquette
1951 US-41
Marquette, MI 49855

Tuesday, June 19, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

Frankenmuth
Bavarian Inn Lodge
1 Covered Bridge Lane
Frankenmuth, MI 48734

Wednesday, June 27, 2018

Click here for BOTH sessions

Click here for A.M. session ONLY

Click here for P.M. session ONLY

HEDIS® is a registered trademark of the National Committee for Quality Assurance.


We now cover digital breast tomosynthesis

Blue Cross Blue Shield of Michigan and Blue Care Network now cover digital breast tomosynthesis, or 3-D mammography, as a screening or diagnostic modality to assess and manage breast cancer for individuals meeting certain criteria, effective March 1, 2018.

Digital breast tomosynthesis may be considered when used in combination with digital screening mammography in high-risk individuals, or a qualified health care provider (ordering provider or radiologist) determines that it should be the primary mammographic study.

For the medical policy, see the billing chart in the April Record.


ClaimsXten™ will include additional professional and outpatient facility editing in July

ClaimsXten will edit additional services for professional and outpatient providers starting in July 2018. These new edits will promote correct coding and simplify our claims payment systems.

Here are highlights:

  • New patient services billed for established patients by professional providers within the established time frames will deny for correct established patient code.
  • Anesthesia services reported with non-anesthesia codes that aren’t eligible to be reported for anesthesia providers will deny for resubmission with the correct anesthesia code.
  • Procedures that allow global component billing that are reported by more than one provider for the same component will deny. Blue Cross’ payment policy only pays up to the global component fee.
  • Claim lines containing services that are unbundled, according to the Centers for Medicare & Medicaid Services National Correct Coding Initiative, aren’t recommended for reimbursement and will deny.

When appropriate, Blue Cross will support the use of modifiers that indicate unique circumstances for individual patients. The use of modifiers should be documented in the patient’s medical records.


Here’s what you need to know about CAQH ProView

To ensure your CAQH ProViewTM credentialing and recredentialing applications are processed efficiently, follow the guidelines below.

Retirement status

  • When answering the question “Are you retired” on your application, you should only select “Yes” if you have completely retired from providing medical or behavioral health services to members. Answering “Yes” signifies that you’re retired from practicing.
  • If you move to a new location, practice group or physician organization, you should include this information in your demographic responses on ProView where indicated. Don’t answer “Yes” to indicate you’ve retired from a location, practice, etc.

Health plan authorization

As previously shared, Blue Cross Blue Shield of Michigan utilizes CAQH to obtain credentialing verifications for physicians during recredentialing cycles. To avoid delays, you must list Blue Cross as one of the health plans authorized to obtain and receive your information from CAQH.

Update your practice information

Review the demographic information for your practices this quarter to ensure its up to date. Pay close attention to the following:

  • If you’re an individual practitioner, review all your practice locations and ensure they’re updated in CAQH Proview, including address, suite numbers and phone numbers.

  • If you’re a practice group, ensure all your practice locations are updated, including suite numbers and phone numbers, through the Provider Self-Service tool.

  • Locations and providers that don’t see patients for appointments should be suppressed so they’re not visible to members in the online directory. Emergency room physicians and administrative addresses are examples of information that shouldn’t be displayed in the directory.

For more information

Here are some resources for providers and their practice managers:

  • For help with CAQH ProView, go to caqh.org/solutions/caqh-proview or call CAQH at 1-888-599-1771.
  • For help with the Provider Self-Service tool, go to bcbsm.com/providers. To sign up for self-service, follow these steps:
    • Click on the Join Our Network tab and then Enrollment and Changes.
    • Click on self-service FAQ.
    • Click on How do I sign up?

You can also call Provider Enrollment at 1-800-822-2761.


Clarification: Authorizations for outpatient infusions

In previous Record articles (October 2017, December 2017 and March 2018), we indicated that certain medical drugs can no longer be administered in an outpatient hospital facility without authorization for the medical drug and location. We wanted to clarify the following:

This authorization requirement only applies to groups that are currently participating in the commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit.

You can find the list of groups that opted out of the Medical Drug Prior Authorization Program on web-DENIS by following these steps:

  1. After logging in to web-DENIS, click on BCBSM Provider Publications and Resources.
  2. Click on Newsletters & Resources.
  3. Under Other Resources,click on Forms.
  4. Click on Physician administered medications.
  5. Click on BCBSM Medical Drug Prior Authorization Program list of groups that have opted out.

Be sure to review the message and notes that precede the list.


Facility

We’ve modified provider appeal time frames, effective June 1

In a March Record article, we let you know that changes were coming to how we’re handling provider audits and appeals. Here are the time frames associated with the provider audit appeals process for professional and non-hospital facility providers, beginning June 1, 2018.

For reconsideration appeal:

  • The health care provider must request an appeal within 30 calendar days of the date on the reporting letter.
  • The provider will receive a response to his or her appeal within 30 calendar days of the date the appeal is received.
  • We’ll adjust claims as needed if we don’t receive a reconsideration appeal within 30 calendar days of the date of the audit finding.

For independent external review:

  • We must receive the request for a review within 30 calendar days of the date of the reconsideration appeal letter.
  • An external peer review of records will take place within 45 calendar days.
  • The provider will be notified of the peer review decision within 30 calendar days of the date that the peer review decision is received.
  • The provider will pay the cost of the peer review if our audit decision is upheld. If our audit decision is reversed, then we’ll absorb the cost. If our findings are partially reversed and partially upheld, we will share the peer review cost proportionate to the results.
  • We’ll adjust claims as needed if we don’t receive a request for an independent external review within 30 calendar days of the date of the appeal uphold letter.

Note: Providers may incur attorney fees and other expenses in preparation for the external peer review; these costs are the providers’ responsibility. The external review ends the appeal process for both Blue Cross Blue Shield of Michigan and the provider.


Here’s an update on the two-midnight rule and provider audits

As of July 31, 2017, Blue Cross Blue Shield of Michigan implemented a prior authorization request process to determine coverage for inpatient care. Using evidence-based criteria, this process focuses on reducing costly overutilization of inpatient services and admissions while providing safe, high-quality care. The prior authorization request process, outlined in the Medicare Plus BlueSM PPO manual, takes precedence over the original Medicare coverage determination process and the “two-midnight” rule.

As such, Provider Audit, through HMS®, a Blue Cross vendor, is not currently conducting short-stay or place-of-service audits. We’re still conducting documentation and compliance audits of valid inpatient orders and Medicare Outpatient Observation Notice, or MOON, forms. In accordance with Centers for Medicare & Medicaid Services and Blue Cross rules, providers should follow documentation and compliance requirements closely to avoid possible recovery of funds during claims processing and post-payment audits.

We’ll continue to audit for procedures on the CMS inpatient-only list. However, because CMS has deferred the enforcement of joint replacement surgery reviews for two years, Provider Audit has no plans to review those admissions in the near term.

If you have any general questions about the audit process, reach out to your provider consultant.

Also, we’re modifying the provider appeals time frames for non-hospital facility and professional providers. For information, see this article.


Benefit Explainer e-learning available

We’ve created a 25-minute, online training presentation for Benefit Explainer. It includes a general overview of the application and how to:

  • Perform a Benefit Package Report search.
  • Read and interpret BPR search screens.
  • Search for general medical and payment policy rules and provider manuals.

The presentation also highlights the new Online Benefits Information tab and other recent upgrades announced in the August 2017 Record article titled “We’re making changes to Benefit Explainer.”

To access the presentation, go to brainshark.com/bcbsm.com/bcbsm/benefit-explainer or visit the Provider Training section of web-DENIS.

  • From the home page of web-DENIS, click on BCBSM Newsletters and Resources.
  • Click on Newsletters and Resources.
  • Click on Provider Training. (The presentation is in the Featured Links section.)

When you access the presentation for the first time, you’ll be asked to sign a guestbook. Check the “Remember Me” box so you can pick up where you left off if you need to stop watching at any point.

Note: Blue Cross Blue Shield of Michigan won’t send solicitation emails or provide your information to anyone for other purposes.


Providers to have one contact for post-acute care authorizations

As Blue Cross Blue Shield of Michigan continues to align functions across our organization, we’ve created a single point of contact for providers to request an authorization for post-acute care admissions, including skilled nursing facilities and long-term acute care hospitals.

As of April 30, 2018, all these requests should be routed to the Precertification Utilization Management team by faxing them to 1-866-411-2573. The process for requesting authorizations can be found here and the forms for faxing can be found on this page, under Forms. As part of the process, all benefits must be verified before you request services.

The Precertification Utilization Management team provides authorizations for acute inpatient hospital settings, inpatient rehabilitation, SNF and Medicare Advantage PPO LTACH cases.

Case Management won’t process requests for enhanced benefits for SNF, LTACH or other extra-contractual benefits as of April 30. These requests will be processed by Precertification Utilization Management. Case Management will continue to process cases for care coordination only. The number for the Blue Cross Engagement Center is 1-800-775 2583.

MESSA is excluded from the precertification and case management programs outlined in this article. All other commercial employer groups, including the auto groups and the URMBT, are included, as well as individual members and Federal Employee Program® members.

If you have any questions, check out the links above.


Here’s how to accurately code for immunosuppression and immunodeficiency

Patients on immunosuppressant medications are commonly assigned a diagnosis code for immunodeficiency. However, in the American Hospital Association’s manual on ICD-10-CM codes, immunosuppression and immunodeficiency are not synonymous. They’re represented by distinctly different ICD-10-CM codes.

Immunodeficiency
Immunodeficiency is caused by a malfunction of the immune system. This malfunction can be either congenital (primary) or acquired.

Congenital immunodeficiency
There are more than 100 primary immunodeficiency disorders, classified by the specific part of the immune system they affect. Examples include:

  • Common variable immunodeficiency
  • Bruton’s disease
  • Severe mixed immunodeficiency syndrome
  • Deficiency of a specific antibody
  • Cyclic neutropenia

Acquired immunodeficiency
This can occur in one of two ways:

  1. As a side effect or adverse effect of a medication that’s correctly prescribed and properly administered. The medicine is used to treat an underlying disease without the intent to alter the immune state, such as antineoplastic chemotherapy drugs or radiation.**

    Example: The physician documents that the patient is immune deficient due to chemotherapy used for treating cancer. The correct code assignment would be T45.1X5-, adverse effect of antineoplastic and immunosuppressive drugs. The required 7th digit is dependent on if the patient is receiving active treatment (A), routine care during the healing or recovery phase (D) or treatment for complications or conditions that arise directly from the condition (S).

  2. As the result of a disease or disorder, such as:
    • Cancer
    • A human immunodeficiency virus infection leading to acquired immunodeficiency syndrome, or AIDS

Immunosuppression
Immunosuppression is caused by medications prescribed to intentionally suppress the immune system. These medications are used to treat various autoimmune diseases, including:

  • Rheumatoid arthritis
  • Sjogren’s syndrome
  • Psoriasis
  • Crohn’s disease

By suppressing the overreactive immune system in patients with these conditions, the immune response triggering the disease process is weakened. Weakening the immune response helps promote remission in afflicted patients.

Immunosuppressant medications are also required for patients who have had an organ transplant. Since the immune system is designed to attack anything foreign within our body, transplanted organs are no exception. By suppressing the immune system, the body is less likely to reject the transplanted organ.

Example: A physician documents that a patient has an immune deficiency and is taking immunosuppressants. The doctor should use code Z79.899 to represent the patient’s long-term immunosuppressant medication therapy. The ICD-10-CM code for immunodeficiency doesn’t provide a specific code to identify these drugs. Since this patient is taking the immunosuppressant medication, with the intent to suppress the immune system, codes for immunodeficiency that’s caused by an adverse effect of drug treatment or from an underlying disease should not be assigned.**

**AHA Coding Clinic for ICD; 2015; third quarter


We now cover digital breast tomosynthesis

Blue Cross Blue Shield of Michigan and Blue Care Network now cover digital breast tomosynthesis, or 3-D mammography, as a screening or diagnostic modality to assess and manage breast cancer for individuals meeting certain criteria, effective March 1, 2018.

Digital breast tomosynthesis may be considered when used in combination with digital screening mammography in high-risk individuals, or a qualified health care provider (ordering provider or radiologist) determines that it should be the primary mammographic study.

For the medical policy, see the billing chart in the April Record.


ClaimsXten™ will include additional professional and outpatient facility editing in July

ClaimsXten will edit additional services for professional and outpatient providers starting in July 2018. These new edits will promote correct coding and simplify our claims payment systems.

Here are highlights:

  • New patient services billed for established patients by professional providers within the established time frames will deny for correct established patient code.
  • Anesthesia services reported with non-anesthesia codes that aren’t eligible to be reported for anesthesia providers will deny for resubmission with the correct anesthesia code.
  • Procedures that allow global component billing that are reported by more than one provider for the same component will deny. Blue Cross’ payment policy only pays up to the global component fee.
  • Claim lines containing services that are unbundled, according to the Centers for Medicare & Medicaid Services National Correct Coding Initiative, aren’t recommended for reimbursement and will deny.

When appropriate, Blue Cross will support the use of modifiers that indicate unique circumstances for individual patients. The use of modifiers should be documented in the patient’s medical records.


Here’s what you need to know about CAQH ProView

To ensure your CAQH ProViewTM credentialing and recredentialing applications are processed efficiently, follow the guidelines below.

Retirement status

  • When answering the question “Are you retired” on your application, you should only select “Yes” if you have completely retired from providing medical or behavioral health services to members. Answering “Yes” signifies that you’re retired from practicing.
  • If you move to a new location, practice group or physician organization, you should include this information in your demographic responses on ProView where indicated. Don’t answer “Yes” to indicate you’ve retired from a location, practice, etc.

Health plan authorization

As previously shared, Blue Cross Blue Shield of Michigan utilizes CAQH to obtain credentialing verifications for physicians during recredentialing cycles. To avoid delays, you must list Blue Cross as one of the health plans authorized to obtain and receive your information from CAQH.

Update your practice information

Review the demographic information for your practices this quarter to ensure its up to date. Pay close attention to the following:

  • If you’re an individual practitioner, review all your practice locations and ensure they’re updated in CAQH Proview, including address, suite numbers and phone numbers.

  • If you’re a practice group, ensure all your practice locations are updated, including suite numbers and phone numbers, through the Provider Self-Service tool.

  • Locations and providers that don’t see patients for appointments should be suppressed so they’re not visible to members in the online directory. Emergency room physicians and administrative addresses are examples of information that shouldn’t be displayed in the directory.

For more information

Here are some resources for providers and their practice managers:

  • For help with CAQH ProView, go to caqh.org/solutions/caqh-proview or call CAQH at 1-888-599-1771.
  • For help with the Provider Self-Service tool, go to bcbsm.com/providers. To sign up for self-service, follow these steps:
    • Click on the Join Our Network tab and then Enrollment and Changes.
    • Click on self-service FAQ.
    • Click on How do I sign up?

You can also call Provider Enrollment at 1-800-822-2761.


DME

Process for billing DME, custom P&O medical supplies changing, starting July 1

After a few years of development, we’re now in the final stages of updating our claims processing system to align with the Centers for Medicare & Medicaid Services’ off-the-shelf policy.

Starting July 1, 2018, all durable medical equipment and medical supply providers who bill for custom prosthetic and orthotic services will be required to bill claims with a separate, CMS-accredited P&O provider PIN. If you bill for custom P&O HCPCS codes and you don’t submit your claim with a separate, CMS-accredited, P&O PIN, your claims will reject as “provider liable.” If you don’t already have your CMS-accredited P&O provider PIN, you can get more information by visiting the National Supplier Clearinghouse** website.

CMS does allow DME, P&O and medical supply providers to bill for specific off-the-shelf orthotic HCPCS codes without any accreditation requirement.

If you still need to update your provider certification information with Blue Cross Blue Shield of Michigan, contact Provider Enrollment and Data Management at 1-800-822-2761.

** Blue Cross Blue Shield of Michigan doesn’t own or control this website.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2017 American Medical Association. All rights reserved.